Lupin’s Biosimilars Strategy Anchored By Japan
This article was originally published in PharmAsia News
Executive Summary
Lupin may have been slow off the block in the biosimilars space in emerging markets compared with some of its Indian peers, but the Mumbai-based firm is hoping that a new strategy centered around its "anchor market" Japan may more than compensate, as well as propelling its entry into the U.S. and Europe.